Skip to records

Therapeutics

229Aging Biotech
100 of 229 records

PLN-101095

Source date not recordedAnalyse record ↗

Dual integrin inhibitor in a recruiting Phase 1a/1b oncology study targeting TGF-beta activation in the tumor microenvironment.

Modality
oral small-molecule dual inhibitor of integrins alpha-v-beta-8 and alpha-v-beta-1
Availability (US)
Phase 1a/1b FORTIFY study Recruiting
Biomarkers
dose-limiting toxicities; treatment-emergent adverse events; objective response; disease control; plasma interferon gamma; pharmacokinetics
Hallmark targeted
extracellular-matrix signaling, TGF-beta activation, altered intercellular communication
Kind
investigational drug
Clinical trials
NCT06270706 — Phase 1, Recruiting on August 3, 2026 registry update